文献速递心律失常血脂与心血管预防

糖尿病对房颤患者症状、治疗及预后的影响:ORBIT-AF注册研究

Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

ORBIT-AF前瞻性注册研究纳入9749例房颤患者,评估合并糖尿病(29.5%)与无糖尿病患者的症状、健康状态、治疗及2年结局差异。糖尿病与更差房颤症状、较低生活质量、更高死亡和住院风险相关,但未增加血栓栓塞或出血事件风险。

要点

  • 房颤合并糖尿病患者症状更重、生活质量更低,且更常接受抗凝治疗。
  • 糖尿病增加全因死亡、心血管死亡及住院风险,但未增加血栓栓塞或出血事件。
  • 糖尿病与房颤进展及新发心衰风险无关。

核心结论

  • 房颤患者中糖尿病与更差症状和更低生活质量相关,并增加死亡和住院风险,但不增加血栓栓塞或出血事件。

研究设计与样本

  • ORBIT-AF为前瞻性、全国性、门诊房颤注册研究,纳入9749例新发或现患房颤患者,比较合并与不合并糖尿病的差异。

主要发现

  • 糖尿病患病率为29.5%,糖尿病患者更年轻,高血压、慢性肾病、心衰、冠心病和卒中比例更高。
  • 糖尿病患者房颤生活质量评分较低:80(IQR 62.5–92.6) vs 82.4(IQR 67.6–93.5),p=0.025。
  • 糖尿病与更高全因死亡风险相关:年龄<70岁 aHR 1.63(95%CI 1.04–2.56),年龄≥70岁 aHR 1.25(95%CI 1.09–1.44)。
  • 糖尿病与更高心血管死亡风险相关:年龄<70岁 aHR 2.20(95%CI 1.22–3.98),年龄≥70岁 aHR 1.24(95%CI 1.02–1.51)。
  • 糖尿病增加非心血管死亡、心源性猝死、住院、心血管住院及非心血管非出血住院风险,但未增加血栓栓塞、出血住院、新发心衰及房颤进展风险。

临床怎么用

  • 对房颤合并糖尿病患者应关注症状负担和生活质量,并加强死亡和住院风险评估与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diabetes is a well-established risk factor for thromboembolism in patients with atrial fibrillation (AF), but less is known about how diabetes influences outcomes among AF patients. OBJECTIVES: This study assessed whether symptoms, health status, care, and outcomes differ between AF patients with and without diabetes. METHODS: The cohort study included 9,749 patients from the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry, a prospective, nationwide, outpatient registry of patients with incident and prevalent AF. Outcomes included symptoms, health status, and AF treatment, as well as 2-year risk of death, hospitalization, thromboembolic events, heart failure (HF), and AF progression. RESULTS: Patients with diabetes (29.5%) were younger, more likely to have hypertension, chronic kidney disease, HF, coronary heart disease, and stroke. Compared to patients without diabetes, patients with diabetes also had a lower Atrial Fibrillation Effects on Quality of Life score of 80 (interquartile range [IQR]: 62.5 to 92.6) versus 82.4 (IQR: 67.6 to 93.5; p = 0.025) and were more likely to receive anticoagulation (p < 0.001). Diabetes was associated with higher mortality risk, including overall (adjusted hazard ratio [aHR]: 1.63; 95% confidence interval [CI]: 1.04 to 2.56, for age <70 years vs. aHR: 1.25; 95% CI: 1.09 to 1.44, for age ≥70 years) and cardiovascular (CV) mortality (aHR: 2.20; 95% CI: 1.22 to 3.98, for age <70 years vs. 1.24; 95% CI: 1.02 to 1.51 for age ≥70 years). Diabetes conferred a higher risk of non-CV death, sudden cardiac death, hospitalization, CV hospitalization, and non-CV and nonbleeding-related hospitalization, but no increase in risks of thromboembolic events, bleeding-related hospitalization, new-onset HF, and AF progression. CONCLUSIONS: Among AF patients, diabetes was associated with worse AF symptoms and lower quality of life, and increased risk of death and hospitalizations, but not thromboembolic or bleeding events.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Echouffo-Tcheugui JB, Shrader P, Thomas L, et al. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017. PMID: 28882229. doi:10.1016/j.jacc.2017.07.755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。